Objective-The present study was designed to evaluate the association of circulating fetuin-A with cardiovascular disease (CVD) and all-cause mortality. Approach and Results-We measured plasma fetuin-A in 1620 patients using an enzyme-linked immunosorbent assay kit.
T he global cardiovascular disease (CVD) death rate reached 293.2 per 100 000 individuals per year in 2013, making CVD the leading cause of noncommunicable-disease deaths worldwide. 1 Cigarette smoking, diabetes mellitus, hyperlipidemia, and hypertension have been recognized as independent risk factors for coronary artery disease (CAD). However, >50% of patients with CAD lack any of the risk factors mentioned above. 2 Several other studies have demonstrated that coronary calcification assessment may facilitate cardiovascular risk prediction independently of conventional risk factors. 3, 4 Fetuin-A (α2-AHSG [alpha 2-HeremansSchmid glycoprotein]) is the most important inhibitor of calcification and has recently received attention as a factor linked with cardiovascular mortality. 5 Fetuin-A is formed by liver cells and secreted into serum, where it complexes with circulating calcium and phosphorus, thereby increasing the solubility of these minerals and suppressing crystal growth and mineral deposition. 6 Hypercalcemia and hyperphosphatemia induce apoptosis and result in the inefficient clearance of calciprotein particles, which leads to the detrimental formation of mineral complexes containing various plasma proteins at sites of tissue injury. Lower fetuin-A levels lead to vascular calcification. 7 Additionally, fetuin-A has anti-inflammatory effects by inhibiting the production of the proinflammatory cytokine tumor necrosis factor. 8 However, fetuin-A is also a natural inhibitor of insulin receptor tyrosine kinase activity, which increases insulin resistance. Fetuin-A knockout mice are characterized by both improved insulin sensitivity and severe calcification of various organs. 9, 10 Because of the opposing pathways, epidemiological studies have not obtained consistent results concerning the association between circulating fetuin-A and the CVD risk. Lower fetuin-A concentrations have predicted increased cardiovascular and all-cause mortality in end-stage renal disease (ESRD) populations, dialysis patients, and the general population, [11] [12] [13] which indicates a potential linkage between the state of aggravating calcification and higher CVD events and mortality. However, several other studies demonstrated that the fetuin-A concentrations were independently positively associated with the presence of CVD events in patients with type 2 diabetes mellitus. These results suggested that the impact of fetuin-A on insulin resistance might be one of the most important mechanisms leading to the deterioration of CAD in these studies.
The discrepancies mentioned above have not been clearly explained. Different disease statuses (presence/lack of type 2 diabetes mellitus or ESRD), different main pathways of the actions of fetuin-A in various diseases, and different analyzed populations (eg, size and age) might influence the results. 15 To date, the potential association between fetuin-A and CVD has been studied in patients with ESRD or type 2 diabetes mellitus, as well as in the community population, [11] [12] [13] [14] but the predictive power of fetuin-A in patients with CAD has not been well studied. The only study with a 6-year follow-up did not find an association between serum fetuin-A and secondary CVD events in patients with stable CAD. 16 Therefore, we conducted this study on a CAD cohort including both acute and stable CAD patients to investigate whether an association existed between fetuin-A and CVD and all-cause mortality. This association might play a potential role in determining a new biomarker for CAD risk.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
The demographic and biochemical characteristics of the baseline fetuin-A levels according to the tertiles (low, ≤0.64 g/L; medium, 0.65-0.86 g/L; and high, 0.87-2.17 g/L) are shown in Table 1 . A total of 1620 patients with CAD were included in the present study. The patients with the highest plasma fetuin-A levels (0.87-2.17 g/L) were younger, had higher body mass indices and triglycerides, and lower C-reactive protein (CRP) levels compared with patients with lowest plasma fetuin-A levels (≤0.64 g/L). Additionally, coronary angiography showed that the coronary artery was less stenosed in patients with higher plasma fetuin-A levels than in patients with the lowest plasma fetuin-A levels. The bivariate correlation analysis between plasma fetuin-A and CVD risk factors is shown in Table 2 . The plasma fetuin-A level was inversely correlated with CRP and positively correlated with triglycerides after adjustment for sex, age, and body mass index.
During a median follow-up of 5.9 years, 206 deaths were recorded (22.4/1000 person-years), 146 of whom died from CVD (15.9/1000 person-years). The interaction between sex and the fetuin-A levels on the risks of all-cause and CVD mortality was not significant. Thus, we combined the data for men and women in the analysis to maximize the statistical power. After adjustment for CVD risk factors (age, sex, body mass index, smoking, leisure-time physical activity, blood pressure, history of diabetes mellitus, history of dyslipidemia, CAD duration, CAD type, CRP, estimated glomerular filtration rate, use of diuretics, use of antihypertensive drugs, use of anticoagulant drugs, use of cholesterol-lowering drugs, and use of antidiabetic drugs), the hazard ratios (HRs) across the second and third tertiles of the baseline plasma fetuin-A levels (using the first tertile as the reference) were 0.65 (95% confidence interval [CI], 0.47-0.91) and 0.48 (95% CI, 0.33-0.70) for all-cause mortality (P for trend <0.001) and 0.65 (95% CI, 0.44-0.96) and 0.51 (95% CI, 0.33-0.78) for cardiovascular mortality (P for trend=0.005), respectively (Table 3) . Multivariate-adjusted cumulative survival curves showed that the risks for all-cause and CVD mortality increased as the fetuin-A levels declined ( Figure 1 ). Furthermore, the risks for all-cause and CVD mortality also increased as the inflammatory imbalance characterized by a low fetuin-A concentration and a high CRP concentration became more severe ( Figure 2 ). The HRs for all-cause and cardiovascular mortality associated with the plasma fetuin-A level by subgroup are presented in Table 4 . No significant interactions were found for the association between the plasma fetuin-A levels and the risk of death by a history of diabetes mellitus, dyslipidemia, CAD type, and the CRP, fasting glucose, high-density lipoprotein, and triglyceride levels. The multivariate-adjusted HRs associated with medium and high fetuin-A levels in patients with CAD without a history of diabetes mellitus were 0.60 (95% CI, 0.40-0.91) and 0.52 (95% CI, 0.33-0.81) for allcause mortality and 0.59 (95% CI, 0.36-0.97) and 0.55 (95% CI, 0.32-0.94) for CVD mortality, respectively. However, this inverse association disappeared among the patients with a history of diabetes mellitus. Similar results were also found The values are the mean (SE) in tertiles for continuous variables with a normal distribution and the median (25th-75th) for variables with a nonnormal distribution. All normally distributed continuous variables were adjusted for age and sex except for age (adjusted for sex only). BMI indicates body mass index; CAD, coronary artery disease; CRP, C-reactive protein; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; and SBP, systolic blood pressure.
*Log transformed before analysis. †Kruskal-Wallis 1-way ANOVA was used for the analysis. ‡General linear model was used after adjusting for age and sex. §χ 2 test was applied for the analysis. in groups divided according to their fasting glucose levels. Higher fetuin-A levels were associated with decreased risks of all-cause and cardiovascular death among patients without a history of dyslipidemia and with high-density lipoprotein <1.04 mmol/L or triglyceride <2.26 mmol/L (all P<0.05). When stratified by the CAD type, the patients in the acute coronary syndrome group in the highest tertile of plasma fetuin-A levels were at a decreased risk of all-cause mortality (HR, 0.35; 95% CI, 0.21-0.57) and cardiovascular mortality (HR, 0.35; 95% CI, 0.20-0.62) compared with those in the lowest tertile. When the patients were divided according to their CRP levels, the protective role of fetuin-A was found only in patients with CRP ≥3 mg/L (Table 4) .
Discussion
In our cohort of hospital-based Chinese patients with CAD, we revealed that patients with higher plasma fetuin-A levels had lower risks of all-cause and CVD mortality after adjustment for a battery of confounding factors. To the best of our knowledge, the present study is the first to demonstrate a significant association of lower plasma fetuin-A with higher allcause and CVD mortality among patients with CAD. As reported previously, fetuin-A exerts a dual impact on CAD. The protective function of fetuin-A against CVD may be explained as follows. First, fetuin-A can inhibit coronary artery calcification (CAC), which is a central characteristic of atherosclerotic CVD, 17 by increasing the blood solubility of calcium and phosphorus and preventing spontaneous mineral precipitation in the vasculature. 6 Additionally, fetuin-A has anti-inflammatory effects by inhibiting the production of the proinflammatory cytokine tumor necrosis factor, 8 which plays a key role in CAD and other manifestations of atherosclerosis. 18 However, fetuin-A can promote the development of CAD by inducing insulin resistance at the tyrosine kinase level. 19 Therefore, the influence of fetuin-A on CAD depends on a combination of various factors in different statuses or conditions.
Earlier epidemiological studies in ESRD and dialysis patients showed that a low fetuin-A level was correlated with Model 1: adjusted for age and sex. Model 2: further adjusted for BMI, smoking, leisure-time physical activity, blood pressure, history of diabetes mellitus (except for fasting glucose), history of dyslipidemia (except for HDL and TG), CAD duration, CAD type, use of diuretics, use of antihypertensive drugs, use of anticoagulant drugs, use of cholesterol-lowering drugs (except for history of dyslipidemia, HDL, and TG), and use of antidiabetic drugs (except for history of diabetes mellitus and fasting glucose). Model 3: further adjusted for CRP and eGFR. All subgroups in the table were adjusted for the variables mentioned above except for the variable in the analysis. BMI indicates body mass index; CAD, coronary artery disease; CRP, C-reactive protein; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; and TG, triglyceride.
increased cardiovascular and all-cause mortality, which was consistent with our results. 5, 13, 20 In terms of stable and acute coronary syndrome, the association between plasma fetuin-A and the CAD risk varied. A previous prospective study with 1049 patients with stable CAD did not find an association between the baseline serum fetuin-A level and the secondary CVD risk after long-term follow-up. 21 Similarly, a link between high plasma fetuin-A levels and a reduced risk of mortality was significant only in patients with acute coronary syndrome in stratified analyses. Furthermore, the plasma fetuin-A levels were inversely correlated with CRP in the current study; this result was consistent with the findings of the nurses' health study, which observed that higher fetuin-A levels were associated with a lower CAD risk only when the CRP levels were also high. 22 An aggravating inflammatory status has been documented in various settings of CAD, especially in acute coronary syndrome, and has a strong association with the clinical outcome. 23 Inflammation has been established as a key promoter of vascular calcification, 24 and the beneficial effects of fetuin-A (ie, inhibiting calcification and triggering an anti-inflammatory response) are most likely more pronounced among people with an inflammatory status. Moreover, combining fetuin-A with the CRP concentration could properly represent the inflammatory status of patients with CAD. 25 Patients with a low fetuin-A and a high CRP concentration were faced with a higher mortality risk than those with a less-severe inflammatory status in the present study. Therefore, our data implied that higher fetuin-A might decrease the CVD risk not only through inhibiting calcification but also through its antiinflammatory effects. The anti-inflammatory properties of fetuin-A may contribute to improvement of the disease conditions of patients with CAD.
The published literature is inconsistent on whether fetuin-A exacerbates or protects against vascular disorders. Most data suggest that fetuin-A has a biphasic effect on atherosclerosis as an atherogenic factor via the induction of insulin resistance or by acting as a protective factor via the inhibition of calcification. 26, 27 Furthermore, some studies have reported that fetuin-A is positively associated with diabetes mellitus, 28, 29 and the plasma fetuin-A concentration has been reported to be associated with the risk of CAD mortality in patients with diabetes mellitus. 12, 14 In contrast, another study did not find an association between plasma fetuin-A and insulin resistance in patients with diabetes mellitus. 30 Interestingly, we found that lower plasma fetuin-A levels were significantly correlated with higher CVD and all-cause mortality only in patients with CAD without diabetes mellitus or with normal fasting glucose levels (<7.0 mmol/L). In CAD patients with diabetes mellitus, there was a negative association of the plasma fetuin-A level with the mortality risk but without significance. Furthermore, the interaction between diabetes mellitus and the fetuin-A level was not significant (P>0.05). These results indicate that the adverse effect of fetuin-A because of an increase in insulin resistance is limited to a certain extent to exacerbation of the CAD risk in these patients.
CAC has been shown to be an independent predictor of CAD 31 and was strongly associated with CAD events, including myocardial infarction and death from CAD. 32 The study also showed that the presence of a high CAC burden was associated with an elevated CAD event rate even among individuals without risk factors, whereas the absence of CAC was associated with a low CAD event rate even among those with many risk factors. 32 The findings suggest that the assessment of CAC is more effective than traditional cardiac risk factors in predicting the clinical outcome. Importantly, circulating fetuin-A is a well-described inhibitor of vascular calcification in patients with ESRD, 33 community-living individuals, 7, 34 and patients with CVD. 35 According to the strong connection among the circulating fetuin-A levels, CAC, and CAD, we hypothesized that high fetuin-A levels lowered the mortality risk in patients with CAD in the present study probably via playing a more efficient role as a calcification inhibitor rather than as an atherogenic factor. However, how the human body regulates the opposite pathways of fetuin-A and whether other undiscovered functions of fetuin-A are involved in CVD are unknown. Further basic and clinical investigations are needed to explain the impact of fetuin-A on CVDs.
The strengths of this study are its prospective design, the relatively large sample size, and the detailed clinical data available for the hospitalized Chinese patients with CAD inclusive of the availability of a wide spectrum of potential confounding variables. The present study also has several limitations. First, the patients with CAD were all enrolled from hospitals, which may have resulted in selection bias. Second, our study could not completely consider other potential confounding factors associated with the plasma fetuin-A levels or CVD development. Third, the effects of residual confounding resulting from measurement error in the assessment of confounding factors could not be completely eliminated. Finally, the majority of the participants were elderly men and women; therefore, the results need to be validated in younger adults.
In conclusion, our prospective data are the first to reveal that lower plasma fetuin-A levels are associated with increased risks of all-cause and CVD mortality in patients with CAD independently of traditional CVD risk factors. The role of plasma fetuin-A as a biomarker or therapeutic target of CAD warrants more investigation.
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